Trial Profile
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Proof of Concept Trial Including Asymptomatic Individuals Using Baricitinib
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Dementia; Mild cognitive impairment
- Focus Biomarker; Pharmacokinetics; Proof of concept
- Acronyms NADALS
- 18 Mar 2024 Planned End Date changed from 1 Oct 2024 to 1 Jun 2025.
- 18 Mar 2024 Planned primary completion date changed from 1 Jul 2024 to 1 Dec 2024.
- 13 Oct 2022 Status changed from not yet recruiting to recruiting.